The effect of statin use on vascular inflammatory biomarkers in people living with HIV: A living systematic review of randomized controlled trials
Asian Pacific Journal of Tropical Medicine · 2026-08 · 19 (8) · 335-343
DOI: 10.4103/apjtm.apjtm_735_25 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Asian Pacific Journal of Tropical Medicine, online erschienen am 29.07.2026. Verfasst von Maryatun Hasan und 4 weiteren Autor:innen. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Objective
To evaluate the effect of statin therapy on biomarkers of vascular inflammation in people living with HIV (PLWH).
Methods
We conducted a living systematic review of randomized controlled trials (RCTs). We searched Scopus, PubMed, Cochrane Library, and Scilit up to April 4, 2025, with a predefined plan for ongoing evidence surveillance and updating. Nine RCTs involving 1 721 participants were included. Data were extracted on changes in key biomarkers, including interleukin-6 (IL-6), high-sensitivity C-reactive protein (hs-CRP), soluble CD14 (sCD14), soluble CD163 (sCD163), oxidized LDL (oxLDL), and lipoprotein-associated phospholipase A 2 (Lp-PLA 2 ). The Cochrane Risk of Bias (RoB 2) tool was used for quality assessment. This review is not intended to be retired from the living mode at this stage.
Results
Statin therapy significantly reduced key biomarkers of monocyte activation and vascular inflammation, particularly IL-6 and sCD14, with effects being most consistent and pronounced with pitavastatin. Pitavastatin also demonstrated greater efficacy in reducing oxLDL and Lp-PLA 2 compared to other statins. Reductions in hs-CRP were inconsistent across studies. A critical finding was that treatment duration was a major modifier of effect, with interventions lasting ≥12 months yielding substantially greater anti-inflammatory benefits. The mechanistic profile suggests statins specifically target the LPS-sCD14 pathway of innate immune activation, which is highly relevant to HIV pathogenesis.
Conclusions
Pitavastatin emerges as the most effective statin for reducing vascular inflammation in PLWH, offering a targeted strategy to mitigate cardiovascular disease risk in this population. These findings, derived from the current iteration of a living systematic review, support the use of long-term pitavastatin therapy for PLWH with evidence of residual inflammation and highlight the need for its inclusion in future clinical guidelines as new evidence continues to emerge.
Zitieren
APA
Hasan, M., Jamil, K. F., Darmawi, D., Syukri, M., & Naufal, M. A. (2026). The effect of statin use on vascular inflammatory biomarkers in people living with HIV: A living systematic review of randomized controlled trials. Asian Pacific Journal of Tropical Medicine, 19(8), 335-343. https://doi.org/10.4103/apjtm.apjtm_735_25
Vancouver
Hasan M, Jamil KF, Darmawi D, Syukri M, Naufal MA. The effect of statin use on vascular inflammatory biomarkers in people living with HIV: A living systematic review of randomized controlled trials. Asian Pacific Journal of Tropical Medicine. 2026;19(8):335-343. doi:10.4103/apjtm.apjtm_735_25
BibTeX
@article{Hasan2026,
author = {Hasan, Maryatun and Jamil, Kurnia F. and Darmawi, Darmawi and Syukri, Maimun and Naufal, Muhammad Alif},
title = {The effect of statin use on vascular inflammatory biomarkers in people living with HIV: A living systematic review of randomized controlled trials},
journal = {Asian Pacific Journal of Tropical Medicine},
year = {2026},
volume = {19},
number = {8},
pages = {335--343},
doi = {10.4103/apjtm.apjtm_735_25}
}
EUVIMED